NAV

Farudodstat

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Farudodstat
DrugBank Accession Number
DB16049
Background

Farudodstat (ASLAN003) is under investigation in clinical trial NCT03451084 (A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 356.329
Monoisotopic: 356.097248645
Chemical Formula
C19H14F2N2O3
Synonyms
  • 2-((3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino)nicotinic acid
  • 2-((3,5-DIFLUORO-3'-METHOXY(1,1'-BIPHENYL)-4-YL)AMINO)-3-PYRIDINECARBOXYLIC ACID
  • 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid
  • 3-PYRIDINECARBOXYLIC ACID, 2-((3,5-DIFLUORO-3'-METHOXY(1,1'-BIPHENYL)-4-YL)AMINO)-
External IDs
  • ASLAN 003
  • ASLAN-003
  • ASLAN003
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
I58WE41H6X
CAS number
1035688-66-4
InChI Key
OMPATGZMNFWVOH-UHFFFAOYSA-N
InChI
InChI=1S/C19H14F2N2O3/c1-26-13-5-2-4-11(8-13)12-9-15(20)17(16(21)10-12)23-18-14(19(24)25)6-3-7-22-18/h2-10H,1H3,(H,22,23)(H,24,25)
IUPAC Name
2-({3,5-difluoro-3'-methoxy-[1,1'-biphenyl]-4-yl}amino)pyridine-3-carboxylic acid
SMILES
COC1=CC(=CC=C1)C1=CC(F)=C(NC2=C(C=CC=N2)C(O)=O)C(F)=C1

References

General References
Not Available
ChemSpider
31144022
BindingDB
119812
ChEMBL
CHEMBL2263632
ZINC
ZINC000103278714

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAcute Myeloid Leukemia1
2RecruitingTreatmentAlopecia Areata (AA)1
1CompletedBasic ScienceHealthy Elderly Subjects (Age ≥55 Years)1
1CompletedBasic ScienceHealthy Subjects (HS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00352 mg/mLALOGPS
logP4.53ALOGPS
logP5.02Chemaxon
logS-5ALOGPS
pKa (Strongest Acidic)1.55Chemaxon
pKa (Strongest Basic)3.95Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area71.45 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity91.99 m3·mol-1Chemaxon
Polarizability34.62 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-052r-0009000000-5c6782f583ac6db18aad
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-0009000000-bdaeab7c644d10bee5ac
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-052r-0009000000-b60a2dfbbd467e6955c7
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-1069000000-cd4d1152c5ce7d0b3a0d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0pdi-4092000000-29710c8a47f1ffd4d128
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-05o0-7090000000-f74883cf61f4b6b98d8c
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at December 15, 2020 18:03 / Updated at July 18, 2023 22:58